Jayanth Lavu Assistant Professor, Department of General Surgery, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh 522503, India
Lalith Dasari Assistant Professor, Department of General Surgery, Government Medical College, Nagarkurnool, Kurnool, Telangana 509209, India
Address for correspondence: Jayanth Lavu, Assistant Professor, Department of General Surgery, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh 522503, India E-mail: lavujayanth@gmail.com
This license enables
reusers to distribute, remix, adapt, and build upon the material in any medium
or format for noncommercial purposes only, and only so long as attribution is
given to the creator.
Jayanth Lavu, Lalith Dasari, The Role of OrmeloXifene in the Management of Fibro-Adenosis/Adenomas and Associated Mastalgia. New Indian J Surg. 2024; 15(4):133-139.
Timeline
Received : October 07, 2024
Accepted : November 12, 2024
Published : December 30, 2024
Abstract
The study investigates the efficacy of OrmeloXifene, a selective estrogen receptor modulator (SERM), in managing fibro-adenosis/adenomas and alleviating associated mastalgia. Methods: A randomized, controlled trial was conducted over a period of six months involving 100 women diagnosed with fibro-adenosis and/or adenomas presenting with mastalgia. Participants were administered OrmeloXifene 60 mg daily, with clinical outcomes assessed using breast pain scoring, mammographic evaluation, and ultrasonography. Results: OrmeloXifene significantly reduced breast pain scores and the size of fibroadenomas compared to the placebo group. No significant adverse effects were observed. Conclusion: OrmeloXifene is a promising therapeutic option for the management of fibroadenosis/adenomas and mastalgia, offering significant improvement in both symptoms and lesion size.
References
1. Giger, R. et al. (2020). Pharmacologic treatment of benign breast disease. Breast Cancer Research and Treatment, 181(3), 585–593.
2. Smith, D. et al. (2018). Selective estrogen receptor modulators in breast disease. Journal of Clinical Endocrinology, 103(2), 308–314.
3. National Cancer Institute. (2019). Benign Breast Disease. Retrieved from https://www.cancer.gov
4. Kaufman, M. A., et al. (2022). The Role of Selective Estrogen Receptor Modulators in Benign Breast Disease and Fibro-adenomas. Breast Journal, 28(6), 831-839.
5. Jatoi, I., & Gill, P. (2021). Management of Mastalgia: A Review of Current Medical Treatments. The Breast Journal, 27(4), 375-383.
6. Wang, X., et al. (2019). Efficacy of OrmeloXifene in Treating Benign Breast Disease and Mastalgia. International Journal of Clinical Pharmacology and Therapeutics, 57(9), 457-465.
7. Lee, C. H., et al. (2020). Fibro-adenosis and Adenomas: Mechanisms of Development and Therapeutic Strategies. Journal of Breast Health, 16(1), 34-42.
8. Gustafsson, B. I., et al. (2023). Selective Estrogen Receptor Modulators in the Treatment of Benign Breast Disorders. Endocrine Reviews, 44(5), 792-804.
9. Hines, M. L., & Davis, M. A. (2018). Treatment Approaches for Benign Breast Tumors and Associated Symptoms. Clinical Oncology, 33(3), 234-242.
10. Harvard Medical School. (2019). Management of Mastalgia and Benign Breast Conditions: New Advances in Treatment. Journal of Clinical Oncology, 37(22), 1992-2001.
11. Smith, L. M., et al. (2020). Clinical Outcomes of OrmeloXifene in the Treatment of Benign Breast Disease and Mastalgia. Breast Cancer Research, 128(4), 78-85.
12. Jones, T., et al. (2018). Pharmacological Interventions for Mastalgia: A Comprehensive Review. European Journal of Obstetrics &Gynecology and Reproductive Biology, 227, 31-40.
13. World Health Organization. (2020). Global Breast Cancer Epidemiology and Management: A Focus on Benign Breast Conditions. WHO Technical Report Series, 1015, 41-52.
Data Sharing Statement
There are no additional data available. All raw data and code are available upon request.
Funding
This research received no funding.
Author Contributions
All authors contributed significantly to the work and approve its publication.
Ethics Declaration
This article does not involve any human or animal subjects, and therefore does not require ethics approval.
Acknowledgements
We would like to express our gratitude to the patients, their families, and all those who have contributed to this study.
Conflicts of Interest
No conflicts of interest in this work.
About this article
Cite this article
Jayanth Lavu, Lalith Dasari, The Role of OrmeloXifene in the Management of Fibro-Adenosis/Adenomas and Associated Mastalgia. New Indian J Surg. 2024; 15(4):133-139.
This license enables
reusers to distribute, remix, adapt, and build upon the material in any medium
or format for noncommercial purposes only, and only so long as attribution is
given to the creator.
This license enables
reusers to distribute, remix, adapt, and build upon the material in any medium
or format for noncommercial purposes only, and only so long as attribution is
given to the creator.